Renovion, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2013-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.renovion.com
Clinical Trials
2
Active:0
Completed:1
Trial Phases
2 Phases
Phase 2:1
Phase 3:1
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Phase 2
1 (50.0%)Phase 3
1 (50.0%)Study to Evaluate ARINA-1 in the Prevention of Bronchiolitis Obliterans Progression in Participants With Bilateral Lung Transplant
Phase 3
Recruiting
- Conditions
- Pre-Bronchiolitis Obliterans Syndrome
- Interventions
- Other: Standard of care only
- First Posted Date
- 2022-12-16
- Last Posted Date
- 2025-07-22
- Lead Sponsor
- Renovion, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT05654922
- Locations
- 🇺🇸
Dignity Health - St. Joseph's Hospital and Medical Center, Phoenix, Arizona, United States
🇺🇸University of California Los Angeles School of Medicine, Los Angeles, California, United States
🇺🇸University of California San Diego Health, San Diego, California, United States
Phase 2a, 28-day Investigational Use Study of ARINA-1 in Non-Cystic Fibrosis Bronchiectasis (NCFBE) With Excess Mucus and Cough
- First Posted Date
- 2022-08-10
- Last Posted Date
- 2025-07-23
- Lead Sponsor
- Renovion, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT05495243
- Locations
- 🇺🇸
University of Alabama - Birmingham, Birmingham, Alabama, United States
🇺🇸National Jewish Hospital, Denver, Colorado, United States
🇺🇸Georgetown University, Washington, District of Columbia, United States
News
No news found